Baxdela TM (Delafloxacin) A Novel Fluoroquinolone for the Treatment of Acute Bacterial Skin and Skin Structure Infections
|
|
- Valerie Juliet Phelps
- 5 years ago
- Views:
Transcription
1 Baxdela TM (Delafloxacin) A Novel Fluoroquinolone for the Treatment of Acute Bacterial Skin and Skin Structure Infections Alexandra Adler, PharmD Candidate; Saira Chaudhry, PharmD, MPH; and Tamara Goldberg, PharmD, BCPS INTRODUCTION Skin and soft tissue infections (SSTI) have become widespread in community and hospital settings. These types of infections can range from mild, which can be self-treated, to severe, life-threatening infections that contribute to mortality. 1 In the past decade, there has been a three-fold increase in hospitalizations due to SSTI. 2,3 The emergence of Community-Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) in the United States has led to a rise in hospital admissions and emergency department (ED) visits by patients with SSTI. 4 There has been a shift from hospital-acquired to community-acquired MRSA purulent SSTI, yet only 38% of empiric treatment regimens prescribed in the ED have included agents with activity against MRSA. 1,3 In October 2013, the FDA published a guidance document to classify more severe and complicated SSTI that would likely require inpatient treatment with parenteral antibiotics. 5 The newly assigned nomenclature introduced the term Acute Bacterial Skin and Skin Struc- Ms. Adler is a PharmD Candidate at Long Island University (LIU) Pharmacy (Arnold & Marie Schwartz College of Pharmacy and Health Sciences) at LIU in Brooklyn, New York. Dr. Chaudhry is a Clinical Assistant Professor in the Pharmacy Practice and Administration Department at the Ernest Mario School of Pharmacy at Rutgers University, in Piscataway, New Jersey. Dr. Goldberg is an Associate Professor of Pharmacy Practice at LIU Pharmacy (Arnold & Marie Schwartz College of Pharmacy and Health Sciences) at LIU in Brooklyn, New York. Drug Forecast is a regular column coordinated by Alan Caspi, PhD, PharmD, MBA, President of Caspi and Associates in New York, New York. Disclosure: The authors report no commercial or financial interests in regard to this article. ture Infections (ABSSSI). ABSSSI can be defined as three categories of infections: cellulitis/erysipelas, wound infection, and major cutaneous abscess. The minimum lesion size to be considered an ABSSSI is 75 cm 2. Common pathogens that may cause ABSSSI include Streptococcus pyogenes and Staphylococcus aureus (most commonly MRSA). 5 Less common bacterial pathogens are Enterococcus faecalis or gram-negative bacteria. ABSSSI are managed by surgical intervention (incision and drainage), culture and sensitivity, and antimicrobial therapy. The recommended agents for ABSSSI when MRSA is suspected are: vancomycin, linezolid, daptomycin, lipoglycopeptides (such as telavancin), tigecycline, and ceftaroline. Empiric coverage for gram-negative organisms is not recommended. The risk of polymicrobial infection is increased in sites of infection that are avascular (such as diabetic foot ulcers). In these cases, broad-spectrum antibiotics with activity against grampositive and gram-negative pathogens, such as beta lactam/beta lactamase inhibitors, tigecycline, or moxifloxacin, are warranted. 6 Baxdela (delafloxacin, Melinta Therapeutics, Inc.) is a novel fluoroquinolone (FQ) that was approved in 2017 for the treatment of ABSSSI, including MRSA SSTI. It is currently being studied for additional indications including community-acquired respiratory tract infections, urinary tract infections (UTIs), and sexually transmitted diseases due to Neisseria gonorrhoeae. 7 This article reviews the pharmacology, pharmacokinetics, drug interactions, clinical efficacy, dosage and administration, safety profile, and place in therapy of Baxdela. PHARMACOLOGY FQs are synthetic antibiotics that inhibit bacterial DNA synthesis, thereby exhibiting bactericidal activity. These antibiotics act on two bacterial enzymes: DNA gyrase and topoisomerase IV. Inhibition of DNA gyrase prevents the relaxation of supercoiled DNA, averting the transcription and translation of DNA. Inhibition of topoisomerase IV prevents separation of replicated chromosomes during cell division. Some FQs have more affinity for one enzyme over another, which translates clinically to differences in spectrum of activity. 8 In gram-negative bacteria, DNA gyrase is more susceptible to inhibition by FQs, whereas in grampositive bacteria, FQs target topoisomerase IV. 9,10 In contrast, delafloxacin binds with equal affinity to and forms a complex with both DNA gyrase and topoisomerase IV, therefore exhibiting good activity against gram-negative, gram-positive, anaerobic, Table 1 Delafloxacin Spectrum of Activity Gram-Positive Gram-Negative Atypical Anaerobes S. aureus (including MRSA) S. epidermidis S. pneumoniae E. faecalis E. faecium Coagulase (-) staphylococci H. influenzae M. catarrhalis N. gonorrhoeae K. pneumoniae P. aeruginosa H. pylori Enterobacter sp. E. coli MRSA = Methicillin-Resistant Staphylococcus aureus Mycoplasma sp. L. pneumophila Chlamydia sp. Ureaplasma sp. C. difficile B. fragilis Prevotella sp. C. perfringens 662 P&T November 2018 Vol. 43 No. 11
2 Figure 1 Chemical Structure of Delafloxacin and atypical pathogens. (See Table 1 for delafloxacin s spectrum of activity.) An additional advantage to dual inhibition is that delafloxacin confers less resistance compared to other FQs. 9 There are a few unique structural modifications that increase the potency of delafloxacin compared to other FQs. One of the major modifications is the change in the substituent on C-7 (Figure 1) 11, making the molecule weakly acidic (pka 5.5). Therefore, the molecule will be neutral in an acidic environment, which enables good transmembrane penetration and higher concentrations in the bacterium. 12,13 This property becomes important in the treatment of ABSSSI, where the infection sites typically have an acidic ph. Once the antibiotic penetrates into the bacteria, the ph is neutral. The change in the ph will cause the antibiotic to become ionized and remain in the bacteria to exert its bactericidal effect. 13 Other modifications include an electronegative chlorine atom on C-8, as well as a large substitution on N-1, which increases the molecular surface area, thereby further enhancing the potency of delafloxacin. 14 PHARMACOKINETICS The pharmacokinetic parameters of delafloxacin have been evaluated in healthy patients. Delafloxacin has a volume distribution (Vd) of 35 L at steady state, which is similar to the total water volume of the body. The drug is primarily excreted renally (65%) in unchanged form, and about 28% is excreted in the feces (unchanged). Clearance is reduced in patients with moderate to severe renal impairment. 15 It is metabolized via phase II reactions, primarily glucoronidation. Delafloxacin does not undergo CYP-mediated metabolism, which is an advantage over other FQs that have interactions with medications that undergo oxidative metabolism. 16 Delafloxacin has been studied in patients with mild, moderate, and severe hepatic dysfunction and was found to be safe and efficacious in those patient populations. 17 The bioavailability of orally administered delafloxacin is 58.8%. Giving oral tablets with high-fat meals or milk reduces the C max by 20%, while the area under the plasma drug concentrationtime curve (AUC) remains unchanged. Because the activity of FQ is dependent on total exposure, delafloxacin can be administered without regard to food. 18 PHARMACODYNAMICS FQs, as a class, display concentrationdependent bactericidal activity. 19 The pharmacodynamic index that best correlates with efficacy is free-drug AUC to MIC ratio (fauc/mic). 20 In a murineinfection model, the median delafloxacin fauc/mic required to achieve a 1-log 10 reduction in bacterial load was 14.3 for both Methicillin-sensitive S.aureus (MSSA) and MRSA isolates (MICs range, mg/l). 21 Based on this pharmacodynamic target, Bhavnani et al. conducted a pharmacokinetic/pharmacodynamic (PK/PD) analysis to estimate the probability of target attainment with delafloxacin in humans. At the MIC 90 of 0.25 mcg/ml for S. aureus, percentage probabilities of attaining fauc/mic associated with 1-log killing was 96.9% on day 1 and 93.1% on day Table 2 Delafloxacin Dosing Route of Dose Administration PO IV 450 mg PO q12 h 300 mg IV q12 h* IV to PO Switch 300 mg IV to 450 mg PO q12 h *Infuse over 1 hour DOSAGE The recommended dose of delafloxacin for ABSSSI is 300 mg intravenously (IV) every 12 hours or 450 mg orally (PO) every 12 hours. For patients with an egfr of ml/min, the IV dose should be adjusted to 200 mg every 12 hours. The IV formulation of delafloxacin contains sulphobutylether-b-cyclodextrin (SBECD) as an inactive ingredient. SBECD may increase serum creatinine and accumulate in patients with renal impairment. The oral dose does not need to be renally adjusted. 11 The use of delafloxacin is not recommended for patients with an egfr < 15 ml/min or for patients on hemodialysis. Both IV and PO dosage forms should not be administered concomitantly with preparations containing multivalent cations such as calcium, magnesium, aluminum, and iron. Based on phase 2 and 3 clinical trials, the duration of delafloxacin therapy for the treatment of ABSSSI has ranged from 5 to 14 days, depending on clinical improvement. (See Table 2 for delafloxacin dosing.) One ongoing phase 3 trial is evaluating a regimen of delafloxacin 300 mg IV twice daily for three days, followed by 450 mg PO twice daily for a total of 5 to 14 days. 23 CLINICAL TRIALS The clinical efficacy and safety of delafloxacin in treating SSTI was studied in two phase 2 trials and two phase 3 trials. Phase II Trials The efficacy and tolerability of delafloxacin (dosed at 300 mg IV and 450 mg IV every 12 hours) was compared to tigecycline (100 mg IV for one dose, followed by 50 mg IV every 12 hours) in 150 patients for 5 to 14 days. 24 This was a randomized, double-blind, multi-center study. Randomization was stratified by infection types: cellulitis (36%), abscess (33%), and wound infection (31%). Clinical cure was defined as the complete resolution of baseline signs or symptoms or improvement, such that no additional antibiotics were needed. S. aureus was the most common pathogen isolated (96 isolates), of which 68 isolates (71%) were MRSA. The MIC 90 values for delafloxa- Renal Dosing Recommendations egfr ml/min egfr ml/min No adjustment needed 200 mg IV q12 h No adjustment needed 200 mg IV switch to 450 mg PO q12 h Vol. 43 No. 11 November 2018 P&T 663
3 cin and tigecycline were 0.06 µg/ml and 0.12 µg/ml, respectively. In the clinically evaluable (CE) population, the clinical cure rates were 94.3% for delafloxacin 300 mg, 92.5% for delafloxacin 450 mg, and 91.2% for tigecycline at the test-ofcure (TOC) visit (14 21 days after the final dose of drug), demonstrating that delafloxacin had comparable efficacy to tigecycline. A second randomized, double-blind phase 2 clinical trial compared the efficacy of delafloxacin (300 mg IV q12 hours) to linezolid (600 mg IV q12 hours) and vancomycin (15 mg/kg IV q12 hours) in 256 patients with ABSSSI. 25 Randomization was stratified by infection category: cellulitis/erysipelas, wound infection, major cutaneous abscess, or burn infection. The study s primary endpoint was to measure clinical response, such as cure (complete resolution), improved (near resolution with no additional antibiotics needed), failure (additional antibiotics needed), and indeterminate (assessment incomplete), at the follow-up visit in the intent-to-treat (ITT) population. The cure rate of delafloxacin (57/81; 70.4%) was comparable to linezolid (50/77; 64.9%) and was statistically better than vancomycin (53/98; 54.1%; P = 0.031). Using a digital measurement, delafloxacin had a significantly greater percentage decrease in erythema compared to vancomycin at follow-up, -96.4% versus -84.5%; P = 0.028). MRSA was the most common pathogen isolated and clinical cure rates were similar among the treatment arms. The MIC 90 values for delafloxacin, linezolid, and vancomycin were 0.12, 2, and 0.5 µg/ml, respectively. Also, the cure rate was statistically higher in the obese patients (body mass index (BMI) 30 kg/m 2 ) who received delafloxacin (78.8%) versus vancomycin (48.8%); P = Phase III Trials The PROCEED studies were two phase 3, multi-center, stratified, randomized, double-blind trials that assessed the efficacy of delafloxacin versus vancomycin plus aztreonam in adults with ABSSSI. The first trial compared intravenous delafloxacin 300 mg versus vancomycin 15 mg/kg plus aztreonam 2 g each given twice daily for 5 to 14 days. 23 Aztreonam was discontinued if gramnegative organisms were not present in baseline cultures. To be included in the study, patients had to have a diagnosis of ABSSSI classified as cellulitis/erysipelas, wound infection, major cutaneous abscess, or burn infection with 75 cm 2 of erythema and 2 signs of systemic infection. The primary efficacy endpoint was the response at 48 to 72 hours (± 2), defined as 20% reduction in erythema of the ABSSSI lesion. The secondary endpoints were investigator-assessed clinical cure (resolution of symptoms) at the follow-up (FU) visit (day 14 ± 1) and late follow-up (LFU) visit (days 21 28). A total of 660 patients were included in the study and stratified by infection type. The mean duration of treatment with delafloxacin was 5 days, and 5.5 days for the vancomycin/aztreonam group. The mean duration for aztreonam was 2 days. The majority of the patients were men (62.9%) and Caucasian (91.1%) with a mean age of 45.8 (± 14.2) years. S. aureus was the most common pathogen identified (n = 324, 66.1%), of which the majority of these isolates were MRSA (n = 169, 52.2%). Most of the patients had either cellulitis/erysipelas (n = 232, 38.8%) or a wound infection (n = 232, 35.2%). A smaller percentage of patients presented with a major cutaneous abscess (n = 167, 25.3%) or burn infection (n = 5, 0.8%). Delafloxacin met non-inferiority criteria, with similar objective response rates across both treatment arms for the primary endpoint. The percentage of responders in the delafloxacin group was 78.2% and 80.9% in the vancomycin/aztreonam group. The cure rates were comparable at FU (52% vs. 50.5%) and at LFU (70.4% vs. 66.6%) for the delafloxacin and vancomycin/aztreonam arms, respectively. In those patients with MRSA, microbiological eradication was 100% and 98.5% in the delafloxacin and vancomycin/aztreonam group, respectively. Of note, delafloxacin (71.7%) had a higher cure rate at LFU compared to the vancomycin/aztreonam group (57.4%) in obese patients (BMI 30 kg/m 2 ). The second phase 3 trial randomized 850 patients to receive either IV delafloxacin (n = 423) 300 mg twice daily for three days, with a mandatory blinded switch to delafloxacin 450 mg PO twice daily, or vancomycin (15 mg/ kg) plus aztreonam (n = 427) 2 g IV twice daily for 5 to 14 days. 26 As in the previous phase 3 trial, aztreonam could be discontinued if the baseline cultures did not reveal gram-negative pathogens. The inclusion criteria for this study were the same as for the previous phase 3 ABSSSI clinical trial. 23 Again, as in the earlier clinical trial, the primary endpoint was the response rate at 48 to 72 hours (± 2), defined as 20% reduction in ABSSSI lesion size, with no further antibiotics. The secondary endpoint was cure rate (complete resolution of symptoms) at the FU and LFU visits. Most of the patients presented with cellulitis/erysipelas (n = 408, 48%), wound infections (n = 223, 26.2%), or major cutaneous abscesses (n = 212, 24.9%), and seven patients had a burn infection (0.8%). Once again, delafloxacin met non-inferiority criteria, with similar hour responses observed in the delafloxacin arm (83.7%) and the vancomycin/aztreonam arm (80.6%). S. aureus, once again, was the most common pathogen. Of those isolates, MRSA was identified in about 32.1% of the patients compared to MSSA (66.3%). When comparing the per-pathogen microbiological response between both treatment arms, it was similar. Adverse Effects The most commonly observed adverse reactions have been gastrointestinal (GI)- related, such as nausea, vomiting, or diarrhea In a phase 2 trial comparing two doses of delafloxacin (300 mg or 450 mg) to tigecycline, the tigecycline group had more GI events (mostly nausea). A convulsion was reported in one patient in the 450-mg delafloxacin group, and was thought to be related to the drug. 24 One phase 3 trial comparing delafloxacin to vancomycin/aztreonam found that the incidence of serious adverse events was equal in the two groups (3.7%). 23 The occurrence of adverse events leading to discontinuation of the medication was lower in the delafloxacin group compared to the vancomycin/aztreonam group (0.9% vs. 4.3%). One patient experienced a hypoglycemic event and two patients experienced hyperglycemia in the delafloxacin group. Blood glucose was monitored in patients for 12 hours post-dose in both groups and no significant differences were reported. In another phase 3 trial comparing oral delafloxacin to vancomycin/aztreonam, similar results were found, with the most common treatmentemergent adverse events related to delafloxacin being nausea (7.7%) and diarrhea (7.7%). Common adverse events seen in 664 P&T November 2018 Vol. 43 No. 11
4 Table 3 Common Adverse Events Seen in the Pooled Phase 3 Trials Type of Adverse Event Delafloxacin n = 741, n (%) Vancomycin/Aztreonam n = 751, n (%) Diarrhea 59 (8%) 29 (4%) Nausea 56 (7.6%) 47 (6.3) Headache 24 (3.2%) 41 (5.5%) Transaminase elevation 22 (3%) 28 (3.7%) Vomiting 17 (2.3%) 18 (2.4%) the pooled phase 3 trials for ABSSI can be found in Table 3. Twelve-lead ECGs were performed as part of the trial protocol s safety assessments and there were no abnormal findings. A randomized, double-blind, placebo-controlled, four-period crossover study conducted among 52 patients assessed the effects of delafloxacin, at therapeutic (300 mg IV) and supratherapeutic (900 mg IV) doses, on the corrected QT interval (QTc) compared to moxifloxacin (400 mg). Delafloxacin was found to have no clinically meaningful increase in QTc, while moxifloxacin produced predicted increases in the QTc. Based on this formal QTc study, QTc prolongation may not be of concern with delafloxacin as compared to other FQs. 27 QTc prolongation was not reported in any of the trials. Phototoxicity also does not seem to be of concern with delafloxacin compared to other FQs. Phototoxicity was not seen with delafloxacin compared with lomefloxacin in a phase 1 trial. 28 WARNINGS AND PRECAUTIONS The FDA has placed a boxed warning regarding the risk of tendonitis, tendon rupture, peripheral neuropathy, CNS effects, and exacerbation of myasthenia gravis for all FQs. Although these adverse reactions have not been reported in clinical trials for delafloxacin, it is recommended to immediately discontinue delafloxacin if a patient experiences any of these adverse reactions. 11 There have been no reports of C. difficile infections in the safety data. Nevertheless, FQs are considered to have a higher risk of causing C. difficile-associated diarrhea (CDAD) compared to other antibiotics. 29 Therefore, a precaution is included for CDAD with the prolonged use of delafloxacin. SUPPLY/STORAGE/STABILITY/ COST Intravenous delafloxacin is supplied as a sterile, lyophilized powder in singledose vials of 300 mg (packaged in cartons of 10). The tablet formulation contains 450 mg of delafloxacin (supplied in bottles of 20 tablets). The injection formulation should be stored at 20 to 25 C (68 77 F). Once reconstituted, the powder may be stored refrigerated or at controlled room temperature for up to 24 hours. 11 The average wholesale price (AWP) of a 450-mg bottle of 20 tablets is $1, ($81/tablet). The AWP for the 300-mg intravenous 10-vial pack is $1, ($159/vial). PATIENT COUNSELING Instruct your patients to report symptoms of tendonitis, tendon rupture, or peripheral neuropathy. Educate your patients on symptoms of CDAD, such as persistent diarrhea with antibiotic use. Remind patients that oral delafloxacin tablets should be taken two hours before or six hours after magnesium- or aluminumcontaining antacids or products containing iron or zinc. Common adverse effects may include nausea, vomiting, headache, and diarrhea. 11 PLACE IN THERAPY Delafloxacin possesses several pharmacological properties that advantageously differentiate it from other FQs. These differences include a broad spectrum of antimicrobial coverage, dualtargeting enzyme activity on DNA gyrase and topoisomerase IV, the absence of drug drug interactions, a diminished effect on QTc interval, and heightened antibacterial activity in an acidic environment. Currently, delafloxacin is approved for the treatment of ABSSSI, as it showed non-inferiority in efficacy compared to standard-of-care therapies. As stated earlier, ABSSSI are mostly caused by gram-positive bacteria. Delafloxacin s broad-spectrum antimicrobial coverage is likely unnecessary for this indication. With this in mind, Melinta Therapeutics is pursuing additional FDA indications for delafloxacin. Currently, there are ongoing phase 3 studies evaluating delafloxacin for the treatment of severe community-acquired bacterial pneumonia and complicated UTIs. Both of these indications may expand the use of delafloxacin in outpatient or inpatient settings. The availability of oral and intravenous formulations of delafloxacin provides the ability to transition patients from IV to oral therapy, which can decrease the cost of care. This may be beneficial in MRSA infections such as bacteremia or bone infections that require prolonged use of an antimicrobial agent. Unfortunately, there is a paucity of data at this time and more randomized controlled trials are warranted to establish efficacy for the aforementioned indications. ` REFERENCES 1. Pallin DJ, Egan DJ, Pelletier AJ, et al. Increased U.S. emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med 2008;51(3): Itani KMF, Merchant S, Lin SJ, et al. Outcomes and management costs in patients hospitalized for skin and skinstructure infections. Am J Infect Control 2011;39(1): Kaye KS, Patel DA, Stephens JM, et al. Rising United States hospital admissions for acute bacterial skin and skin structure infections: recent trends and economic impact. PLoS ONE. 2015;10(11):e Frazee BW, Lynn J, Charlebois ED, et al. High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann Emerg Med 2005;45(3): U.S. Food and Drug Administration, Center for Drug Evaluation and Research Guidance for Industry. Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment 2013 Draft Guidance. Available at: fda.gov/downloads/drugs/guidances/ ucm pdf. Accessed December 3, Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014;59(2):e10 e52. Vol. 43 No. 11 November 2018 P&T 665
5 7. Food and Drug Administration. FDA approves Baxdela to treat acute bacterial skin and skin structure infections (ABSSSI). June 17, Available at: / Orig1s00 0,208611Orig1s000Approv.pdf. Accessed December 3, Aldred K, Kerns R, Osheroff N. Mechanism of quinolone action and resistance. Biochemistry 2014;53(10): Nilius AM, Shen LL, Hensey-Rudloff D, et al. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob Agents Chemother 2003; 47(10): Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis 2005;41(suppl 2):S120 S Baxdela [package insert]. Lincolnshire, IL: Melinta Therapeutics Inc; Flamm R, Rhomberg P, Huband M, Farrell D. In vitro activity of delafloxacin tested against isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother 2016;60(10), Lemaire S, Tulkens PM, VanBambeke F. Contrasting effects of acidic ph on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus. Antimicrob Agents Chemother 2011; 55(2): Candel FJ, Peñuelas M. Delafloxacin: design, development and potential place in therapy. Drug Des Devel Ther 2017;11: Hoover R, Hunt T, Benedict M, et al. Safety, tolerability, and pharmacokinetic properties of intravenous delafloxacin after single and multiple doses in healthy volunteers. Clin Ther 2016;38(1): Paulson SK, Wood-Horrall RN, Hoover R, et al. The pharmacokinetics of the CYP3A substrate midazolam after steadystate dosing of delafloxacin. Clin Ther 2017;39(6): Hoover R, Marbury TC, Preston RA, et al. Clinical pharmacology of delafloxacin in patients with hepatic impairment. J Clin Pharmacol 2017;57(3): Hoover R, Hunt T, Benedict M, et al. Single and multiple ascending-dose studies of oral delafloxacin: effects of food, sex, and age. Clin Ther 2016;38(1): Almer LS, Hoffrage JB, Keller EL, et al. In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against gram-positive and gram-negative organisms. Antimicrob Agents Chemother 2004;48(7): Connors KP, Kuti JL, Nicolau DP. Optimizing antibiotic pharmacodynamics for clinical practice. Pharmaceut Anal Acta 2013;4: Burak E, Bortolon E, Molstad D, et al. Pharmacokinetics and pharmacodynamics of delafloxacin in S. aureus murine thigh infection models. In: Proceedings of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, Poster A American Society for Microbiology, Washington, D.C. 22. Bhavnani SM, Zhang L, Ambrose PG, et al. Population pharmacokinetic and pharmacokinetic-pharmacodynamic target attainment analyses for delafloxacin to support dose selection for the treatment of patients with acute bacterial skin and skin structure infections. In: Proceedings of IDWeek 2017, San Diego, CA, Poster The Infectious Diseases Society of America, Arlington, VA. 23. Pullman J, Gardovskis J, Farley B, et al. Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a phase 3, double-blind, randomized study. J Antimicrob Chemother 2017;72(12): Riordan WO, Mehra P, Manos P, et al. A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections. Int J Infect Dis 2015;30: Kingsley J, Mehra P, Lawrence LE, et al. A randomized, double-blind, phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin. J Antimicrob Chemother 2016;71(3): Riordan WO, McManus AM, Teras J, et al. A global phase 3 study of delafloxacin compared to vancomycin/aztreonam in patients with acute bacterial skin and skin structure infections [published online October 26, 2016]. Open Forum Infectious Diseases 2016;3(suppl 1):S1347 doi: /ofid/ofw Litwin JS, Benedict MS, Thorn MD, et al. A thorough QT study to evaluate the effects of therapeutic and supratherapeutic doses of delafloxacin on cardiac repolarization. Antimicrob Agents Chemother 2015;59(6): Ferguson J, Lawrence L, Paulson S, et al. Assessment of phototoxicity potential of delafloxacin in healthy male and female subjects: a phase I study. In Proceedings of the Fifty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy with the International Society of Chemotherapy s International Congress of Chemotherapy and Infection, San Diego, CA, Poster F-1198a. American Society of Microbiology, Washington, DC. 29. Dingle KE, Didelot X, Quan TP, et al. Effects of control interventions on Clostridium difficile infection in England: an observational study. Lancet 2017;17(4): n 666 P&T November 2018 Vol. 43 No. 11
Scottish Medicines Consortium
Scottish Medicines Consortium daptomycin 350mg powder for concentrate for solution for infusion (Cubicin ) Chiron Corporation Limited No. (248/06) 10 March 2006 The Scottish Medicines Consortium (SMC)
More informationChoosing the Ideal Antibiotic Therapy and the Role of the Newer Fluoroquinolones in Respiratory Tract Infections
...CLINICIAN INTERVIEW... Choosing the Ideal Antibiotic Therapy and the Role of the Newer Fluoroquinolones in Respiratory Tract Infections An interview with Robert C. Owens, Jr., PharmD, Clinical Pharmacy
More informationNew Antibiotics for MRSA
New Antibiotics for MRSA Faculty Warren S. Joseph, DPM, FIDSA Consultant, Lower Extremity Infectious Diseases Roxborough Memorial Hospital Philadelphia, Pennsylvania Faculty Disclosure Dr. Joseph: Speaker
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationPeriod of study: 12 Nov 2002 to 08 Apr 2004 (first subject s first visit to last subject s last visit)
Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency of Bayer's
More informationAZITHROMYCIN, DOXYCYCLINE, AND FLUOROQUINOLONES
AZITHROMYCIN, DOXYCYCLINE, AND FLUOROQUINOLONES Update in Medicine and Primary Care Whitney R. Buckel, PharmD, BCPS-AQ ID System Antimicrobial Stewardship Pharmacist Manager OBJECTIVES 1. List three antibiotics
More informationLe infezioni di cute e tessuti molli
Le infezioni di cute e tessuti molli SCELTE e STRATEGIE TERAPEUTICHE Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Treatment of complicated skin and skin structure infections
More informationETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections
ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections Robin Isaacs Chief Medical Officer, Entasis Therapeutics Dr. Isaacs is a full-time employee of Entasis Therapeutics.
More informationWhat s next in the antibiotic pipeline?
What s next in the antibiotic pipeline? Jennifer Tieu, Pharm.D., BCPS Clinical Pearls OSHP Spring Meeting Mercy Hospital April 13, 2018 Objective 2 Describe the drug class and mechanism of action of antibiotics
More informationLefamulin Evaluation Against Pneumonia (LEAP 1) Phase 3 Topline Results. September 18, 2017
Lefamulin Evaluation Against Pneumonia (LEAP 1) Phase 3 Topline Results September 18, 2017 Safe Harbor and Disclaimer Any statements in this presentation about future expectations, plans and prospects
More informationLefamulin: a novel pleuromutilin antibiotic class George Dimopoulos MD, PhD, FCCP, FCCM, FECMM
: a novel pleuromutilin antibiotic class George Dimopoulos MD, PhD, FCCP, FCCM, FECMM Department of Critical Care, University Hospital ATTIKON National and Kapodistrian University of Athens, Medical School
More informationmoxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering
moxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering 05 November 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationUSA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION
VIRBAC CORPORATION USA Product Label http://www.vetdepot.com P.O. BOX 162059, FORT WORTH, TX, 76161 Telephone: 817-831-5030 Order Desk: 800-338-3659 Fax: 817-831-8327 Website: www.virbacvet.com CLINTABS
More informationProtein Synthesis Inhibitors
Protein Synthesis Inhibitors Assistant Professor Dr. Naza M. Ali 11 Nov 2018 Lec 7 Aminoglycosides Are structurally related two amino sugars attached by glycosidic linkages. They are bactericidal Inhibitors
More informationIntroduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More informationBacterial Resistance of Respiratory Pathogens. John C. Rotschafer, Pharm.D. University of Minnesota
Bacterial Resistance of Respiratory Pathogens John C. Rotschafer, Pharm.D. University of Minnesota Antibiotic Misuse ~150 million courses of antibiotic prescribed by office based prescribers Estimated
More informationBacterial skin and soft tissues infections (SSTI) are one of the most common 1. infections among different age groups
Bacterial skin and soft tissues infections (SSTI) are one of the most common 1 infections among different age groups Gram-positive bacteria are the most frequently isolated pathogens from SSTI, with a
More informationClinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: HIM*, Medicaid
Clinical Policy: (Zyvox) Reference Number: CP.PMN.27 Effective Date: 09.01.06 Last Review Date: 02.19 Line of Business: HIM*, Medicaid Coding Implications Revision Log See Important Reminder at the end
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationCefazolin vs. Antistaphyloccal Penicillins: The Great Debate
Cefazolin vs. Antistaphyloccal Penicillins: The Great Debate Annie Heble, PharmD PGY2 Pediatric Pharmacy Resident Children s Hospital Colorado Microbiology Rounds March 22, 2017 Image Source: Buck cartoons
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationAntibiotic Updates: Part I
Antibiotic Updates: Part I Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationParatek Announces FDA Approval of NUZYRA (Omadacycline)
Paratek Announces FDA Approval of NUZYRA (Omadacycline) Modernized Tetracycline for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) and Acute Skin and Skin Structure Infections (ABSSSI)
More informationPrinciples of Antimicrobial Therapy
Principles of Antimicrobial Therapy Key Points Early and rapid diagnosis of infection and prompt initiation of appropriate antimicrobial therapy, if warranted, are fundamental to reducing the mortality
More informationSIVEXTRO (tedizolid phosphate) oral tablet ZYVOX (linezolid) oral suspension and tablet
ZYVOX (linezolid) oral suspension and tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
More informationTreatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani
Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani 30-1-2018 1 Objectives of the lecture At the end of lecture, the students should be able to understand the following:
More information4 th and 5 th generation cephalosporins. Naderi HR Associate professor of Infectious Diseases
4 th and 5 th generation cephalosporins Naderi HR Associate professor of Infectious Diseases Classification Forth generation: Cefclidine, cefepime (Maxipime),cefluprenam, cefoselis,cefozopran, cefpirome
More informationMARBOCYL FD SUMMARY OF PRODUCT CHARACTERISTICS
MARBOCYL FD SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MARBOCYL FD 1 %, powder and solvent for solution for injection, for cats and dogs. 2. QUALITATIVE AND QUANTITATIVE
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More information3/23/2017. Kathryn G. Smith, PharmD PGY1 Pharmacy Resident Via Christi Hospitals Wichita, Inc. Kathryn G. Smith: Nothing to disclose
Kathryn G. Smith, PharmD PGY1 Pharmacy Resident Via Christi Hospitals Wichita, Inc Kathryn G. Smith: Nothing to disclose Describe the new updates and rationale for them Relay safety concerns with use of
More informationThe pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,
More informationAppropriate Antimicrobial Therapy for Treatment of
Appropriate Antimicrobial Therapy for Treatment of Staphylococcus aureus infections ( MRSA ) By : A. Bojdi MD Assistant Professor Inf. Dis. Dep. Imam Reza Hosp. MUMS Antibiotics Still Miracle Drugs Paul
More informationSkin and Soft Tissue Infections Emerging Therapies and 5 things to know
2011 MFMER slide-1 Skin and Soft Tissue Infections Emerging Therapies and 5 things to know Aaron Tande, MD Assistant Professor of Medicine October 27, 2017 Division of INFECTIOUS DISEASES 2011 MFMER slide-2
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Nuzyra) Reference Number: CP.PMN.## Effective Date: 11.20.18 Last Review Date: 02.19 Line of Business: Commercial, TBD HIM*, Medicaid Coding Implications Revision Log See Important Reminder
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrocare 50 mg/ml Solution for Injection for Cattle, Pigs, Dogs and Cats (UK, IE, FR) Floxadil 50 mg/ml Solution for Injection
More informationDOSAGE FORMS AND STRENGTHS Otic Suspension: Each OTIPRIO vial contains 1 ml of 6% (60 mg/ml) ciprofloxacin otic suspension. (3)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OTIPRIO safely and effectively. See full prescribing information for OTIPRIO. OTIPRIO (ciprofloxacin
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationPharmaceutical Form Ciprofloxacin 2 mg/ml Solution for infusion. Applicant Name Strength. Ciprofloxacin Nycomed. Ciprofloxacin Nycomed
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTE OF ADMINISTRATION, APPLICANT/ MARKETING AUTHORISATION HOLDER IN THE MEMBER STATES Marketing Member State Authorisation
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Enrotron 50 mg/ml Solution for injection for cattle, pigs, dogs and cats
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrotron 50 mg/ml Solution for injection for cattle, pigs, dogs and cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each
More informationAntibacterials. Recent data on linezolid and daptomycin
Antibacterials Recent data on linezolid and daptomycin Patricia Muñoz, MD. Ph.D. (pmunoz@micro.hggm.es) Hospital General Universitario Gregorio Marañón Universidad Complutense de Madrid. 1 GESITRA Reasons
More informationANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin
ANTIBIOTICS USED FOR RESISTACE BACTERIA 1. Vancomicin Vancomycin is used to treat infections caused by bacteria. It belongs to the family of medicines called antibiotics. Vancomycin works by killing bacteria
More informationClinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: Oregon Health Plan
Clinical Policy: (Zyvox) Reference Number: CP.PMN.27 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy
More informationCentral Nervous System Infections
Central Nervous System Infections Meningitis Treatment Bacterial meningitis is a MEDICAL EMERGENCY. ANTIBIOTICS SHOULD BE STARTED AS SOON AS THE POSSIBILITY OF BACTERIAL MENINGITIS BECOMES EVIDENT, IDEALLY
More informationAntibiotic Stewardship Program (ASP) CHRISTUS SETX
Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:
More informationCME/CE QUIZ CME/CE QUESTIONS. a) 20% b) 22% c) 34% d) 35% b) Susceptible and resistant strains of typical respiratory
CME/CE QUIZ CME/CE QUESTIONS Continuing Medical Education Accreditation This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for
More informationAntimicrobials Update
Antimicrobials Update Rosie Amini, PharmD. BCPS Antimicrobial Stewardship Program Coordinator Swedish Medical Center Disclosures: Dr. Amini has no significant financial interest in any of the products
More informationCHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Antibiotics One of the most commonly used group of drugs In USA 23
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marbocare 20 mg/ml solution for injection for cattle and pigs (UK, IE, FR) Odimar 20 mg/ml solution for injection for cattle
More informationGUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes
More informationStaph Cases. Case #1
Staph Cases Lisa Winston University of California, San Francisco San Francisco General Hospital Case #1 A 60 y.o. man with well controlled HIV and DM presents to clinic with ten days of redness and swelling
More informationPharmacology Week 6 ANTIMICROBIAL AGENTS
Pharmacology Week 6 ANTIMICROBIAL AGENTS Mechanisms of antimicrobial action Mechanisms of antimicrobial action Bacteriostatic - Slow or stop bacterial growth, needs an immune system to finish off the microbe
More informationOther β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL
Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL David P. Nicolau, PharmD, FCCP, FIDSA Director, Center for Anti-Infective Research and Development Hartford Hospital
More information48 th Annual Meeting. IDWeek and ICAAC: The Cliffs Notes Version. Skin and Soft Tissue Infections. Skin and Soft Tissue Infections.
48 th Annual Meeting IDWeek and ICAAC: The Cliffs Notes Version Yanina Pasikhova Pharm.D., BCPS-AQ ID, AAHIVP Infectious Diseases Pharmacist Moffitt Cancer Center Navigating the Oceans of Opportunity Skin
More informationDelafloxacin: The One Fluoroquinolone to Rule Them All
Delafloxacin: The One Fluoroquinolone to Rule Them All The Use of Delafloxacin in Skin and Soft Tissue Infections Casey Stauffer, PharmD PGY- Pharmacy Practice Resident Methodist Hospital and Methodist
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT RONAXAN 20mg Tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substance : Doxycycline (as doxycycline
More informationمادة االدوية المرحلة الثالثة م. غدير حاتم محمد
م. مادة االدوية المرحلة الثالثة م. غدير حاتم محمد 2017-2016 ANTIMICROBIAL DRUGS Antimicrobial drugs Lecture 1 Antimicrobial Drugs Chemotherapy: The use of drugs to treat a disease. Antimicrobial drugs:
More informationFor analyst certification and disclosures please see page 7
Physician Survey Survey of Healthcare Professionals on Community-Acquired Bacterial Pneumonia We conducted a survey on prescribing habits for community-acquired bacterial pneumonia (CABP) in order to better
More informationAntimicrobial Therapy
Antimicrobial Therapy David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle Disclosure: Dr. Spach has no significant financial interest in any of the
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metrobactin 500 mg tablets for dogs and cats (AT, BE, BG, CY, CZ, DE, EL, ES, FR, HR, HU, IE, IT, LU, NL, PL, PT, RO, SI,
More informationDiscover the. Discover the. innovative science. Veraflox (pradofloxacin) Veraflox. Efficacy. Safety. Ease-of-use.
Discover the Discover the innovative science. science of Veraflox Oral Veraflox. Suspension for Cats Efficacy. Safety. Ease-of-use. An unprecedented combination of efficacy, safety and ease-of-use. Designed
More information11/10/2016. Skin and Soft Tissue Infections. Disclosures. Educational Need/Practice Gap. Objectives. Case #1
Disclosures Selecting Antimicrobials for Common Infections in Children FMR-Contemporary Pediatrics 11/2016 Sean McTigue, MD Assistant Professor of Pediatrics, Pediatric Infectious Diseases Medical Director
More informationThe β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationAntimicrobial Stewardship in Ambulatory Care
Antimicrobial Stewardship in Ambulatory Care Nila Suntharam, M.D. May 5, 2017 Dr. Suntharam indicated no potential conflict of interest to this presentation. She does not intend to discuss any unapproved/investigative
More informationAppropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases
Appropriate Management of Common Pediatric Infections Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases It s all about the microorganism The common pathogens Viruses
More informationNew Drugs for Bad Bugs- Statewide Antibiogram
New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationfolate-derived cofactors purines pyrimidines Sulfonamides sulfa drugs Trimethoprim infecting bacterium to perform DNA synthesis cotrimoxazole
Folate Antagonists Enzymes requiring folate-derived cofactors are essential for the synthesis of purines and pyrimidines (precursors of RNA and DNA) and other compounds necessary for cellular growth and
More informationCurricular Components for Infectious Diseases EPA
Curricular Components for Infectious Diseases EPA 1. EPA Title Promoting antimicrobial stewardship based on microbiological principles 2. Description of the A key role for subspecialists is to utilize
More informationMARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS
MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MARBOCYL 10%, solution for injection for cattle and swine 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Marbofloxacin...100.0
More informationAntibacterial Resistance: Research Efforts. Henry F. Chambers, MD Professor of Medicine University of California San Francisco
Antibacterial Resistance: Research Efforts Henry F. Chambers, MD Professor of Medicine University of California San Francisco Resistance Resistance Dose-Response Curve Antibiotic Exposure Anti-Resistance
More informationAntimicrobial stewardship: Quick, don t just do something! Stand there!
Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger
More informationThe Journal of Emergency Medicine, Vol. 44, No. 6, pp. e397 e412, 2013 Copyright Ó 2013 Elsevier Inc. Printed in the USA. Open access under CC BY-NC-ND license. 0736-4679 http://dx.doi.org/10.1016/j.jemermed.2012.11.050
More informationPharmacokinetics. Absorption of doxycycline is not significantly affected by milk or food, but coadministration of antacids or mineral supplements
Pharmacokinetics. Absorption of doxycycline is not significantly affected by milk or food, but coadministration of antacids or mineral supplements should be avoided. PDR Drug Summaries are concise point-of-care
More informationAuthor - Dr. Josie Traub-Dargatz
Author - Dr. Josie Traub-Dargatz Dr. Josie Traub-Dargatz is a professor of equine medicine at Colorado State University (CSU) College of Veterinary Medicine and Biomedical Sciences. She began her veterinary
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Selectan 300 mg/ml solution for injection for cattle and swine. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:
More informationNorthwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16
Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16 These criteria are based on national and local susceptibility data as well as Infectious Disease Society of America
More informationSrirupa Das, Associate Director, Medical Affairs, Tushar Fegade, Manager, Clinical Research Abbott Healthcare Private Limited, Mumbai.
Indian Medical Gazette JUNE 2015 225 Comparative A Randomized, Open Label, Prospective, Comparative Evaluating the Efficacy and Safety of Fixed Dose Combination of Cefpodoxime 200 Mg + Clavulanic Acid
More informationAntimicrobial Stewardship in the Hospital Setting
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 12 Antimicrobial Stewardship in the Hospital Setting Authors Dan Markley, DO, MPH, Amy L. Pakyz, PharmD, PhD, Michael Stevens, MD, MPH Chapter Editor
More informationPrinciples of Anti-Microbial Therapy Assistant Professor Naza M. Ali. Lec 1
Principles of Anti-Microbial Therapy Assistant Professor Naza M. Ali Lec 1 28 Oct 2018 References Lippincott s IIIustrated Reviews / Pharmacology 6 th Edition Katzung and Trevor s Pharmacology / Examination
More informationAntibiotic stewardship in long term care
Antibiotic stewardship in long term care Shira Doron, MD Associate Professor of Medicine Division of Geographic Medicine and Infectious Diseases Tufts Medical Center Boston, MA Consultant to Massachusetts
More informationAntibiotic Abyss. Discussion Points. MRSA Treatment Guidelines
Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California
More informationPart II SUMMARY OF PRODUCT CHARACTERISTICS. Each tablet contains 25 mg Clindamycin (as Clindamycin Hydrochloride)
Clindacyl 25mg Tablets Vm 08007/4104 Part II SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CLINDACYL 25 MG TABLETS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationAntibiotics & treatment of Acute Bcterial Sinusitis. Walid Reda Product Manager. Do your antimicrobial options meet your needs?
Antibiotics & treatment of Acute Bcterial Sinusitis Walid Reda Product Manager Do your antimicrobial options meet your needs? Antimicrobial Effects: What s involved? Effect in Humans: Serum concentration
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Marbotab P 20 mg tablets for dogs and cats
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marbotab P 20 mg tablets for dogs and cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substance:
More informationGeneral Approach to Infectious Diseases
General Approach to Infectious Diseases 2 The pharmacotherapy of infectious diseases is unique. To treat most diseases with drugs, we give drugs that have some desired pharmacologic action at some receptor
More informationClinical Practice Standard
Clinical Practice Standard 1-20-6-1-010 TITLE: INTRAVENOUS TO ORAL CONVERSION FOR ANTIMICROBIALS A printed copy of this document may not reflect the current, electronic version on OurNH. APPLICABILITY:
More informationANNEX III AMENDMENTS TO THE SUMMARY OF PRODUCT CHARACTERISTICS AND PACKAGE LEAFLET
ANNEX III AMENDMENTS TO THE SUMMARY OF PRODUCT CHARACTERISTICS AND PACKAGE LEAFLET 1 AMENDMENTS TO BE INCLUDED IN THE RELEVANT SECTIONS OF THE SUMMARY OF PRODUCT CHARACTERISTICS FOR MOXIFLOXACIN CONTAINING
More information*Corresponding author. Tel:! ; Fax:! ; Members are listed in the Acknowledgements section.
J Antimicrob Chemother 2017; 72: 3471 3480 doi:10.1093/jac/dkx329 Advance Access publication 5 October 2017 Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial
More informationEXCEDE Sterile Suspension
VIAL LABEL MAIN PANEL PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN READ SAFETY DIRECTIONS FOR ANIMAL TREATMENT ONLY EXCEDE Sterile Suspension 200 mg/ml CEFTIOFUR as Ceftiofur Crystalline Free
More informationDurata Therapeutics Presents New Comprehensive Review of the Efficacy and Safety Data of Dalbavancin and New In Vitro Findings at IDWeek 2013
October 2, 2013 Durata Therapeutics Presents New Comprehensive Review of the Efficacy and Safety Data of Dalbavancin and New In Vitro Findings at IDWeek 2013 SAN FRANCISCO, Oct. 2, 2013 (GLOBE NEWSWIRE)
More informationOral antibiotics are not always straight forward
Oral antibiotics are not always straight forward OPAT Regional Workshop 1 st May 2018 Fiona Robb, Antimicrobial Pharmacist NHS Greater Glasgow & Clyde Introduction Describe NHS GGC s Oral vs IV Antibiotics
More informationPinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu
Search for: Search Search Does levaquin cover anaerobes Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu Levofloxacin, sold under the trade names Levaquin among others, is an antibiotic.
More informationPrinciples of Antimicrobial therapy
Principles of Antimicrobial therapy Laith Mohammed Abbas Al-Huseini M.B.Ch.B., M.Sc, M.Res, Ph.D Department of Pharmacology and Therapeutics Antimicrobial agents are chemical substances that can kill or
More informationInappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012
Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton
More informationSystemic Antimicrobial Prophylaxis Issues
Systemic Antimicrobial Prophylaxis Issues Pierre Moine Department of Anesthesiology University of Colorado Denver 3 rd International Conference on Surgery and Anesthesia OMICs Group Conference The Surgical
More information